Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Helman Website

Lee J. Helman, M.D.

Selected Publications

1)  El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ.
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.
Cell Growth Differ. 1: 325-31, 1990.
[Journal]
2)  Zhan S, Shapiro D, Zhan S, Zhang L, Hirschfeld S, Elassal J, Helman LJ.
Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer.
J Biol Chem. 270: 27983-6, 1995.
[Journal]
3)  Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ.
The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.
J Biol Chem. 272: 30822-7, 1997.
[Journal]
4)  Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH.
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.
J. Clin. Oncol. 29: 4541-7, 2011.
[Journal]
5)  Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI, Jahromi MS, Xekouki P, Szarek E, Walker R, Lasota J, Raffeld M, Klotzle B, Wang Z, Jones L, Zhu YJ, Wang Y, Waterfall J, O'Sullivan M, Bibikova M, Pacak K, Stratakis CA, Janeway KA, Schiffman JD, Fan J, Helman LJ, Meltzer PS.
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor.
Cancer Discov. 3: 648-57, 2013.
[Journal]
6)  Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ.
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study.
Cancer. 2014.
[Journal]
7)  Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ.
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Clin. Cancer Res. 20: 1190-203, 2014.
[Journal]
8)  Arnaldez FI, Helman LJ.
New Strategies in Ewing's Sarcoma: Lost in Translation?.
Clin. Cancer Res. [Epub ahead of print], 2014.
[Journal]
9)  Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton P, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Janeway KA, Weigel BJ, Randall RL, Meltzer PS, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Uren A, Patel S, Trent JM, Savage SA, Mirabello L, Reinke D, Barkauskas DA, Smith MA, Bernstein ML, Kirsch DG, Krailo MD.
Towards a Drug Development Path that Targets Metastatic Progression in Osteosarcoma.
Clin. Cancer Res. 2014.
[Journal]
10)  Kang Z, Yu Y, Zhu YJ, Davis S, Walker R, Meltzer PS, Helman LJ, Cao L.
Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
Oncogene. [Epub ahead of print], 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/23/2014.